Gilead SciencesFoster City, California, United States
Disclosure information not submitted.
392 - Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances
Tuesday, October 21, 20252:09 PM - 2:21 PM US ET